The company reported revenue of $10.97 billion and earnings of $1.34 on a per-share and adjusted basis, compared to the ...

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

Abbott stock fell early Wednesday after the health giant narrowly missed fourth-quarter sales views and reported in-line ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...

CEO Robert Ford also plans to expand sales of the company’s Lingo over-the-counter glucose sensors after a limited rollout.

The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say.

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus ...